Clal Insurance’s AbbVie ABBV Stock Holding History

Clal Insurance’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,000	Closed	-$613K	–	169
2022 Q2	$613K	Hold	4,000	–	–	0.01%	140
2022 Q1	$648K	Buy	+4,000	New	+$581K	0.01%	141

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clal Insurance's ABBV Position: Q3 2022 in Review

Clal Insurance sold out of AbbVie (ABBV) in Q3 2022, closing a stake of 4,000 shares — an estimated $613K sold.

Clal Insurance first reported a position in ABBV in Q1 2022 and held it in 2 quarters. The position peaked at $648K in Q1 2022. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Clal Insurance reported no remaining AbbVie position as of Q3 2022 after selling out during the quarter.
Clal Insurance sold 4,000 AbbVie shares in Q3 2022, an estimated $613K.
Clal Insurance first reported a position in AbbVie in Q1 2022 and held it in 2 quarters.
Clal Insurance's AbbVie position peaked at $648K in Q1 2022.
2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Clal Insurance's 13F filing for Q3 2022, filed 14 Nov 2022.